Jaguar Animal Health Inc. (JAGX)
NASDAQ:JAGX
Want to see JAGX full AI Analyst Report?
JAGX Stock Chart & Stats
$1.28
-$0.07(-5.93%)
At close: 4:00 PM EST
$1.28
-$0.07(-5.93%)
Day’s Range― - ―
52-Week Range$2.53 - $186.55
Previous CloseN/A
Volume188.05K
Average Volume (3M)71.56K
Market Cap
$1.48M
Enterprise Value$27.28M
Total Cash (Recent Filing)$968.00K
Total Debt (Recent Filing)$43.61M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1279.95
Shares Outstanding401,265
10 Day Avg. Volume169,351
30 Day Avg. Volume71,560
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.13
Price to Sales (P/S)0.19
P/FCF Ratio0.38
Enterprise Value/Market Cap18.37
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit3.53
Enterprise Value/Ebitda-0.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.2
Revenue Forecast (FY)$2.46M
Bulls Say, Bears Say
Bulls Say
FDA-approved Commercial ProductHaving an FDA-approved, commercial-stage product (Mytesi) provides a durable revenue foundation and lowers clinical/regulatory risk versus pre-revenue peers. A marketed specialty GI therapy supports recurring prescription sales, established distribution channels, and optionality to leverage crofelemer into adjacent human and animal indications over time.
Improved Operating Cash Flow In 2025A reversal to positive operating and free cash flow in 2025 materially improves near-term financing flexibility and shows the business can convert sales to cash. Sustained cash generation would reduce reliance on dilutive financing and support investment in commercialization and product development over the next several quarters.
Debt And Royalty Restructurings Eased Near-term BurdenNegotiated amendments to royalty and debt agreements pushed out maturities, lowered repayment amounts, and removed some dilution, materially reducing near-term cash obligations. These structural fixes extend the liquidity runway and improve the company's capacity to execute commercial operations and pursue strategic options.
Bears Say
Stressed Balance Sheet With Negative EquityNegative stockholders' equity and rising leverage signal impaired capital structure and limit financial flexibility. This increases reliance on external funding, raises borrowing costs, can trigger covenants, and constrains the company’s ability to invest or absorb shocks without dilutive or restrictive financing solutions.
Volatile Revenue And Structural LossesSharp revenue swings and persistent large operating losses indicate the cost base is not scaled to sales. Despite healthy gross margins, the inability to produce consistent operating profits undermines sustainable free cash flow and makes long-term investment and growth dependent on stabilizing top-line and continuing cost discipline.
Listing And Governance Constraints From Preferred StockIssuing Series Q preferred to reduce royalty obligations trades cash relief for restrictive investor rights: consent rights, liquidation preference, and limits on future equity. These covenants can constrain strategic decisions, future financings, and increase potential dilution risk for common shareholders over the medium term.
Jaguar Animal Health News
JAGX FAQ
What was Jaguar Animal Health Inc.’s price range in the past 12 months?
Jaguar Animal Health Inc. lowest stock price was $2.53 and its highest was $186.55 in the past 12 months.
What is Jaguar Animal Health Inc.’s market cap?
Jaguar Animal Health Inc.’s market cap is $1.48M.
When is Jaguar Animal Health Inc.’s upcoming earnings report date?
Jaguar Animal Health Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 90 days.
How were Jaguar Animal Health Inc.’s earnings last quarter?
Currently, no data Available
Is Jaguar Animal Health Inc. overvalued?
According to Wall Street analysts Jaguar Animal Health Inc.’s price is currently Overvalued.
Does Jaguar Animal Health Inc. pay dividends?
Jaguar Animal Health Inc. does not currently pay dividends.
What is Jaguar Animal Health Inc.’s EPS estimate?
Jaguar Animal Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jaguar Animal Health Inc. have?
Jaguar Animal Health Inc. has 401,265 shares outstanding.
What happened to Jaguar Animal Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Jaguar Animal Health Inc.?
Currently, no hedge funds are holding shares in JAGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jaguar Animal Health Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
JAGX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented meaningful strategic and clinical positives — a sizable non-dilutive upfront/licensing arrangement, manufacturing revenue upside, and compelling proof-of-concept data with 12%–37% reductions in parenteral support and a targeted NDA timeline (H1 2027) for MVID. However, these positives are balanced by near-term commercial and financial challenges: YoY revenue decline, sustained and growing operating losses (net loss to $53.6M; Non-GAAP recurring EBITDA loss $48.1M), declining Mytesi prescription volumes, and increased dependency on partner milestone payments and manufacturing revenue under the out-license. Overall, the call communicated promising development and BD catalysts that could be transformative long term but also highlighted significant short-term financial pressures and commercialization trade-offs.View all JAGX earnings summariesTechnical Analysis
Galmed Pharmaceuticals
―
Soligenix
―
Revelation Biosciences
―
Dermata Therapeutics
―
60 Degrees Pharmaceuticals, Inc.
―
Ownership Overview
25.95% Insiders
15.13% Mutual Funds
― Other Institutional Investors
58.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---